© 2021 MJH Life Sciences and Oncology Nursing News. All rights reserved.
© 2021 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
September 23, 2021
Real-world evidence recently presented at the 2021 AUA Annual Meeting showed that high adherence rates and favorable prostate-specific antigen (PSA) response were observed in men with nmCRPC who were treated with apalutamide.